- Home
- ABBV
ABBV
AbbVie Inc.
as 06-30-2025 10:30am EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 338.3B | IPO Year: | N/A |
| Target Price: | $213.14 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.34 | EPS Growth: | -30.38 |
| 52 Week Low/High: | $163.52 - $218.66 | Next Earning Date: | 07-24-2025 |
| Revenue: | $57,367,000,000 | Revenue Growth: | 5.45% |
| Revenue Growth (this year): | 8.48% | Revenue Growth (next year): | 8.19% |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
3 Dividend Stocks to Double Up on Right Now
Simply Wall St.
2 days ago
Those who invested in AbbVie (NYSE:ABBV) five years ago are up 126%
Motley Fool
2 days ago
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Insider Monkey
2 days ago
AbbVie’s Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
Zacks
3 days ago
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
Zacks
3 days ago
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
Investor's Business Daily
4 days ago
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
Zacks
4 days ago
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.